Dr. Benjamin T. Chappell, M.D.
OB-GYN (Obstetrics & Gynecology) (Obstetrics & Gynecology Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 28
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Obstetrics & Gynecology Physician primary
TN license 45073
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Medicare patients and services
- Medicare patients, 2024
- 28
- Services billed
- 52
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 63 | 63 |
| Established patient office or other outpatient visit, 20-29 minutes | 61 | 55 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 21 | 21 |
| Screening mammography | 15 | 15 |
| Screening 3d breast mammography | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Estradiol Other prescribers in Memphis, TN | 26 |
| Estradiol-Norethindrone Acetat (estradiol/norethindrone acet) | 13 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Memphis, TN | 13 |
| Zolpidem Tartrate Other prescribers in Memphis, TN | 13 |
| Dotti (estradiol) Other prescribers in Memphis, TN | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 10 payments worth $4,830 in total to this clinician.
| Lina Medical USA Inc | $2,800 |
|---|---|
| Organon LLC | $1,549 |
| Davol Inc. | $215 |
| Integra Lifesciences Corporation | $142 |
| Coopersurgical, Inc. | $100 |
| Hologic Sales and Service, LLC | $24.27 |
| Compensation for services other than consulting (speaking, faculty) | $2,800 |
|---|---|
| Speaking at a medical education program | $1,521 |
| Food and Beverage | $509 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Organon LLC Sep 12, 2025 | Speaking at a medical education program NEXPLANON · ETONOGESTREL | $1,521 |
| Lina Medical USA Inc Aug 17, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionPayment for participation in a Dine and Learn with other physicians. | $1,400 |
| Lina Medical USA Inc Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionPayment made for providing content for a Technique Spotlight document. | $1,400 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $1,250 in research payments for these studies, mostly to the institutions running them.
- A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
Sumitomo Pharma America, Inc. · Recruiting · NCT05862272
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.